<?xml version="1.0" encoding="UTF-8"?><html xmlns="http://www.w3.org/1999/xhtml" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:protege="http://protege.stanford.edu/plugins/owl/protege#" xmlns:xsp="http://www.owl-ontologies.com/2005/08/07/xsp.owl#" xmlns:Thesaurus="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#" xmlns:dublincorens="http://purl.org/dc/elements/1.1/"  version="XHTML+RDFa 1.0" ><body>                               NIH Public Access <br />                                Author Manuscript <br />                                Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                            Published final edited form as: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                             Cancer Res. 2010 November 1; 70(21): 8517&#226;&#8364;&#8220;8525. doi:10.1158/0008-5472.CAN-10-1242. <br />  <br />  <br />  <br />                            Hippo Pathway Effector Yap Ovarian Cancer Oncogene <br />  <br />                            Chad A. Hall1, Runsheng Wang2, Jiangyong Miao6, Esther Oliva6, Xiaoyun Shen2, Thomas <br />                            Wheeler2,3, Susan G. Hilsenbeck3,4, Sandra Orsulic6,7, Scott Goode1,2,3,5 <br />                            1 Department Molecular Human Genetics, Baylor College Medicine, Houston, TX <br />  <br />                            2   Department Pathology, Baylor College Medicine, Houston, TX <br />                            3   Dan L. Duncan Cancer Center, Baylor College Medicine, Houston, TX <br />                            4   Lester Sue Smith Breast Center, Baylor College Medicine, Houston, TX <br />                            5Department Molecular Cellular Biology, Program Development, Program Cell and <br />                            Molecular Biology, Baylor College Medicine, Houston, TX <br />                            6Department Pathology, Massachusetts General Hospital Harvard Medical School, Boston, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                            MA <br />  <br />                            <span id='am-1' about='protege:abstract' typeof='owl:Thing'>Abstract</span> <br />                                  The Hippo Pathway regulates organ size tumorigenesis Drosophila mammals altered <br />                                  variety human cancers, remains unclear Hippo Pathway prognostic significance <br />                                  cancer patients. Here Yap, human homolog key transcriptional target of <br />                                  Hippo pathway, plays conserved role promoting tumorigenesis fly ovary and <br />                                  human ovarian cancer. While studies linking Yap cancer tissues focused overall <br />                                  Yap levels, demonstrate time subcellular levels Yap exceptionally <br />                                  strong association poor patient <span id='am-4' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-5' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-6' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-7' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-8' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-9' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-10' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-11' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-12' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-13' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-14' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-15' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-16' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-17' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-18' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-19' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-20' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-21' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-22' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-23' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-24' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-25' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-26' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-27' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-28' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-29' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-30' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-31' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-32' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-33' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-34' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-35' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-36' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-37' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-38' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-39' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-40' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-41' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-42' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-43' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-44' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-45' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-46' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-47' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-48' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-49' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-50' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-51' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-52' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-53' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-54' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-55' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-56' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-57' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-58' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-59' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-60' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-61' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-62' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-63' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-64' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-65' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-66' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-67' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-68' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-69' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-70' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-71' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-72' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-73' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-74' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-75' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-76' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-77' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-78' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-79' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-80' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-81' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span>survival</span>. Specifically, high levels nuclear Yap, low levels <br />                                  cytoplasmic phosphorylated-Yap, associated poor survival ovarian cancer. Patients with <br />                                  high nuclear Yap low cytoplasmic phosphorylated-Yap approximately 50% lower 5- <br />                                  year survival, combination independent prognostic marker survival, an <br />                                  exceptionally high hazard ratio 7.8. We Yap2 predominantly expressed Yap isoform <br />                                  ovarian surface epithelium epithelial ovarian cancers. Overexpression Yap2 and <br />                                  phosphorylation-defective Yap2-5SA immortalized ovarian surface epithelium cells resulted in <br />                                  increased cell proliferation, resistance cisplatin-induced apoptosis, faster cell migration, and <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                  anchorage independent growth, Yap knockdown resulted increased sensitivity cisplatin- <br />                                  induced apoptosis. Findings argue Hippo signaling pathway defines important pathway <br />                                  progression ovarian cancer. <br />  <br />  <br />                            Keywords <br />                                  Drosophila Follicular Epithelium; Human Ovarian Cancer; Yap; Hippo Pathway; Basolateral <br />                                  Junction Signaling <br />  <br />  <br />  <br />  <br />                            Corresponding Author: Scott Goode, Phone: 713-798-8828, FAX: 713-798-5838, sgoode@bcm.tmc.edu. <br />                            7Present Address: Women&#226;&#8364;&#8482;s Cancer Research Institute Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical <br />                            Center, Los Angeles, CA <br />                             Hall et al.                                                                                             Page 2 <br />  <br />  <br />                                Introduction <br />                                          Epithelial ovarian cancer lethal gynecologic malignancy fifth most <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          prevalent cause cancer death women United States (1). Due internal <br />                                          localization ovaries, lack specific symptoms, lack effective screening methods, <br />                                          ovarian cancer usually remains undetected reached advanced stage (2). Nearly <br />                                          70% patients present late stage disease spread organs abdominal <br />                                          cavity 5 year survival patients remains 30%(1). The current standard <br />                                          care includes surgical resection tumor followed treatment platinum- and <br />                                          taxane-based chemotherapies (3). <br />  <br />                                          An important step development targeted personalized treatments ovarian <br />                                          cancer identification molecules involved development progression. One method <br />                                          identifying molecules study model organisms. Several laboratories <br />                                          developed mouse models ovarian cancer targeted disruption expression of <br />                                          candidate ovarian cancer tumor suppressors oncogenes proposed site origin of <br />                                          ovarian cancer- ovarian surface epithelium (OSE) (4). Although useful the <br />                                          characterization candidate molecules, mammalian ovary does lend itself large- <br />                                          scale forward genetic screens identify new molecules. <br />  <br />                                          We hypothesized Drosophila ovary serve powerful genetic model screen <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          molecules disrupted inhuman ovarian cancer. Mutations basolateral junction proteins <br />                                          discs large, lethal giant larvae, scribble fly ovary result tumor-like phenotypes, <br />                                          including overproliferation, loss cell polarity, invasion (5&#226;&#8364;&#8220;7). In order identify new <br />                                          molecules involved ovarian tumorigenesis, performed large-scale genetic modifier <br />                                          screen genes enhance discs large ovarian tumor <span id='am-82' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-83' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-84' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-85' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-86' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-87' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-88' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-89' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-90' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-91' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-92' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-93' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-94' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-95' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-96' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-97' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-98' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-99' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-100' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-101' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-102' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-103' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-104' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-105' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-106' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-107' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-108' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-109' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-110' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-111' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-112' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-113' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-114' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-115' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-116' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-117' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-118' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-119' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-120' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-121' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-122' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-123' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-124' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-125' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-126' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-127' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-128' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-129' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-130' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-131' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-132' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-133' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-134' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-135' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-136' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-137' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-138' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-139' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-140' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-141' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-142' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-143' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-144' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-145' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-146' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-147' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-148' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-149' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-150' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-151' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-152' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-153' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-154' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-155' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-156' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-157' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-158' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-159' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span>phenotype</span>, identified warts. <br />                                          Further analysis revealed warts loss caused tumors Drosophila ovary (7). <br />  <br />                                          Warts kinase regulates organ size tumorigenesis fly tissues. Warts acts <br />                                          network tumor suppressors encode receptor, scaffolding, signaling molecules, <br />                                          collectively known Hippo pathway, crucial function repress oncogene Yki, <br />                                          transcriptional coactivator (8). In mammals, Warts homologs Lats-1 Lats-2 <br />                                          phosphorylate Yki homolog Yap (Yes associated protein (9)) S127, allowing 14-3-3 <span id='am-3' about='protege:TO' typeof='owl:Thing'>to</span> <br />                                          bind Yap retain cytoplasm, blocking Yap&#226;&#8364;&#8482;s ability coactivate transcription <br />                                          nucleus (8). Yap located genomic region, 11q22, amplified variety <br />                                          cancers including ovarian cancer, Yap levels predict patient outcome hepatocellular <br />                                          carcinoma (11,12). Further, Yap overexpression murine liver causes massive liver <br />                                          overgrowth tumorigenesis (10). <br />  <br />                                          Here report overexpression human Yap induces tumorigenesis Drosophila <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          ovary, suggesting plays conserved role ovarian tumorigenesis. Consistent a <br />                                          role Yap human ovarian cancer, high nuclear Yap (nYap) low <br />                                          cytoplasmic phosphorylated-S127-Yap (cpYap) associated poor survival. Further, we <br />                                          overexpression Yap2, phosphorylation resistant allele Yap2, Yap2-5SA, <br />                                          immortalized OSE cells (IOSE) resulted increased proliferation, resistance cisplatin- <br />                                          induced apoptosis, loss contact inhibition, increased cell migration, anchorage <br />                                          independent growth. Together, findings indicate Yap acts oncogene ovarian <br />                                          cancer promoting disease progression development chemoresistance. <br />  <br />  <br />  <br />  <br />                                               Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                                Page 3 <br />  <br />  <br />                                Materials Methods <br />                                Drosophila <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Yap overexpressing flies constructed using FLP-out technique. Adult female y,w,hs- <br />                                             FLP; act&gt;y+&gt;Gal4, UAS-GFP/UAS-Yap-S127A flies heat shocked 37 &#194;&#176;C 2 min, <br />                                             incubated 25 &#194;&#176;C 3 days. Ovaries dissected processed described (7). <br />  <br />                                Human Tissue Samples <br />                                             The tissue microarray (TMA) comprised 2 blocks cores duplicate formalin <br />                                             fixed, paraffin embedded archival primary ovarian carcinoma samples 70 patients <br />                                             (median age 59.8, range 22&#226;&#8364;&#8220;93)(Table 1). The patients treated Massachusetts <br />                                             General Hospital 1989&#226;&#8364;&#8220;2004 IRB approved protocol. H&amp;E sections all <br />                                             samples reviewed certified gynecologic pathologist selected tumor cores. <br />  <br />                                Immunohistochemistry <br />                                             Normal ovary sections ovarian cancer TMA analyzed immunohistochemistry <br />                                             described (13). No antigen retrieval used anti-Yap 1:100 (H-125, Santa Cruz <br />                                             Biotechnology, Inc.), 0.01M citrate buffer (pH 6.0) used anti-phosphorylated- <br />                                             S127-Yap 1:50 (4911S, Cell Signaling Technologies). Immunostained slides evaluated <br />                                             nuclear cytoplasmic Yap pYap described (14) independent scorers, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             TW (certified pathologist), CH, SO SG, blinded data. Scores were <br />                                             combined using 2/3 majority. Proportion scores did vary considerably samples and <br />                                             analyzed. Intensity scores 0 (none) 1 (weak) assigned low category, <br />                                             2 (intermediate) 3 (strong) assigned high category Yap pYap. <br />  <br />                                Cell Lines <br />                                             All cell lines grown 1:1 mixture MCDB 105 medium (Sigma-Aldrich Co., M6395) <br />                                             Medium 199 (Sigma-Aldrich Co., M5017) supplemented 10% FBS, 25ug/ml <br />                                             gentamycin, 10 U/ml Penicilin, 10 ng/ml streptomycin. TheIOSE-80 cell line (15), which <br />                                             normally senesces passage 20, immortalized infection hTERT expressing <br />                                             retrovirus (Addgene Plasmid #1774), followed selection 100 ug/ml G418 10 days. <br />                                             The resulting cell line, 80T, able grow 90 passages. Yap knockdown lines were <br />                                             infecting 80T cells pGIPZ lentiviruses Open Biosystems manufacturer <br />                                             instructions followed selection 1ug/ml puromycin 10 days. shYap-7 corresponds <br />                                             plasmid Cat. No. RHS4430-98818907, shYap-8 RHS4430-98525388, shYap-9 to <br />                                             RHS4430-98893379. Yap overexpressing cell lines infecting 80T cells with <br />                                             pQCXIH-myc retroviruses containing Yap2 Yap2-5SA (16), followed selection 200 <br />                                             &#206;&#188;g/ml hygromycin 10 days. The approximate percentage cells culture expressing <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             indicated constructs selection was: Nontargeting (90%), shYap7 (50%), shYap8 <br />                                             (80%), shYap9 (80%), vector (n/a), Yap2 (60%), Yap2-5SA (90%). <br />  <br />                                Sequence Analysis <br />                                             Whole RNA isolated tumors reverse transcribed using iScript cDNA <br />                                             synthesis kit (BioRad). Yap fragments PCR amplified cDNAs. T7 T3 sequence <br />                                             added upstream following Yap specific primers: Yap Left Forward: <br />                                             CCGGGCATCAGATCGTGCA; Yap Left Reverse: GCTGAAGCCGAGTTCATCAT; Yap <br />                                             Right Forward: TTCAGCCATGAACCAGAGAA; Yap Right Reverse: <br />                                             AGTCTGCCTGAGGGCTCTA. PCR products sequenced (LoneStar Labs) using T7 and <br />                                             T3 primers analyzed <span id='am-160' about='Thesaurus:TESSE01' typeof='owl:Thing'><span id='am-161' property="Thesaurus:Preferred_Name" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-162' property="rdfs:label" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-163' property="Thesaurus:Preferred_Name" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-164' property="Thesaurus:code" content="TEESS18" datatype="rdf:PlainLiteral"></span><span id='am-165' property="Thesaurus:code" content="TEESS07" datatype="rdf:PlainLiteral"></span><span id='am-166' property="Thesaurus:code" content="TEESS21" datatype="rdf:PlainLiteral"></span><span id='am-167' property="Thesaurus:Preferred_Name" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-168' property="rdfs:label" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-169' property="rdfs:label" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-170' property="Thesaurus:Preferred_Name" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-171' property="rdfs:label" content="Mutation analysis" datatype="rdf:PlainLiteral"></span><span id='am-172' property="rdfs:label" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-173' property="Thesaurus:Preferred_Name" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-174' property="Thesaurus:Preferred_Name" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-175' property="Thesaurus:Preferred_Name" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-176' property="Thesaurus:code" content="TEESS15" datatype="rdf:PlainLiteral"></span><span id='am-177' property="Thesaurus:code" content="TEESS22" datatype="rdf:PlainLiteral"></span><span id='am-178' property="Thesaurus:code" content="TEESS20" datatype="rdf:PlainLiteral"></span><span id='am-179' property="Thesaurus:Preferred_Name" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-180' property="Thesaurus:Preferred_Name" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-181' property="Thesaurus:Preferred_Name" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-182' property="Thesaurus:Preferred_Name" content="Insertion mutation" datatype="rdf:PlainLiteral"></span><span id='am-183' property="Thesaurus:Preferred_Name" content="Knock-out" datatype="rdf:PlainLiteral"></span><span id='am-184' property="Thesaurus:Preferred_Name" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-185' property="rdfs:label" content="Missense mutation" datatype="rdf:PlainLiteral"></span><span id='am-186' property="Thesaurus:Preferred_Name" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-187' property="Thesaurus:Preferred_Name" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-188' property="rdfs:label" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-189' property="rdfs:label" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-190' property="rdfs:label" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-191' property="Thesaurus:code" content="TEESS17" datatype="rdf:PlainLiteral"></span><span id='am-192' property="Thesaurus:Preferred_Name" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-193' property="Thesaurus:code" content="TEESS19" datatype="rdf:PlainLiteral"></span><span id='am-194' property="rdfs:label" content="Gene knockout" datatype="rdf:PlainLiteral"></span><span id='am-195' property="rdfs:label" content="knockout" datatype="rdf:PlainLiteral"></span><span id='am-196' property="Thesaurus:code" content="TEESS02" datatype="rdf:PlainLiteral"></span><span id='am-197' property="rdfs:label" content="cell survival" datatype="rdf:PlainLiteral"></span><span id='am-198' property="Thesaurus:code" content="TEESS01" datatype="rdf:PlainLiteral"></span><span id='am-199' property="Thesaurus:code" content="TEESS10" datatype="rdf:PlainLiteral"></span><span id='am-200' property="Thesaurus:code" content="TEESS09" datatype="rdf:PlainLiteral"></span><span id='am-201' property="Thesaurus:Preferred_Name" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-202' property="rdfs:label" content="RNA Interference" datatype="rdf:PlainLiteral"></span><span id='am-203' property="rdfs:label" content="Frameshift mutation" datatype="rdf:PlainLiteral"></span><span id='am-204' property="rdfs:label" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-205' property="Thesaurus:Preferred_Name" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-206' property="rdfs:label" content="RNA interference pathway" datatype="rdf:PlainLiteral"></span><span id='am-207' property="Thesaurus:code" content="TEESS08" datatype="rdf:PlainLiteral"></span><span id='am-208' property="rdfs:label" content="Targeted mutation" datatype="rdf:PlainLiteral"></span><span id='am-209' property="rdfs:label" content="Induced mutation" datatype="rdf:PlainLiteral"></span><span id='am-210' property="Thesaurus:code" content="TEESS24" datatype="rdf:PlainLiteral"></span><span id='am-211' property="Thesaurus:Preferred_Name" content="Point mutation" datatype="rdf:PlainLiteral"></span><span id='am-212' property="Thesaurus:code" content="TEESS05" datatype="rdf:PlainLiteral"></span><span id='am-213' property="Thesaurus:Preferred_Name" content="Deletion mutation" datatype="rdf:PlainLiteral"></span><span id='am-214' property="Thesaurus:code" content="TEESS13" datatype="rdf:PlainLiteral"></span><span id='am-215' property="Thesaurus:code" content="TEESS12" datatype="rdf:PlainLiteral"></span><span id='am-216' property="Thesaurus:code" content="TEESS06" datatype="rdf:PlainLiteral"></span><span id='am-217' property="Thesaurus:code" content="TEESS16" datatype="rdf:PlainLiteral"></span><span id='am-218' property="Thesaurus:Preferred_Name" content="survival" datatype="rdf:PlainLiteral"></span><span id='am-219' property="rdfs:label" content="Deleterious mutation" datatype="rdf:PlainLiteral"></span><span id='am-220' property="Thesaurus:Preferred_Name" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-221' property="Thesaurus:code" content="TEESS14" datatype="rdf:PlainLiteral"></span><span id='am-222' property="Thesaurus:code" content="TEESS11" datatype="rdf:PlainLiteral"></span><span id='am-223' property="Thesaurus:Preferred_Name" content="Silent mutation" datatype="rdf:PlainLiteral"></span><span id='am-224' property="Thesaurus:Preferred_Name" content="phenotype" datatype="rdf:PlainLiteral"></span><span id='am-225' property="rdfs:label" content="Nonsense mutation" datatype="rdf:PlainLiteral"></span><span id='am-226' property="rdfs:label" content="Germline mutation" datatype="rdf:PlainLiteral"></span><span id='am-227' property="Thesaurus:code" content="TEESS25" datatype="rdf:PlainLiteral"></span><span id='am-228' property="rdfs:label" content="Novel mutation" datatype="rdf:PlainLiteral"></span><span id='am-229' property="rdfs:label" content="lethal phenotype" datatype="rdf:PlainLiteral"></span><span id='am-230' property="rdfs:label" content="Mutation" datatype="rdf:PlainLiteral"></span><span id='am-231' property="Thesaurus:code" content="TEESS23" datatype="rdf:PlainLiteral"></span><span id='am-232' property="Thesaurus:Preferred_Name" content="null mutants" datatype="rdf:PlainLiteral"></span><span id='am-233' property="Thesaurus:code" content="TEESS04" datatype="rdf:PlainLiteral"></span><span id='am-234' property="Thesaurus:code" content="TEESS03" datatype="rdf:PlainLiteral"></span><span id='am-235' property="Thesaurus:Preferred_Name" content="null allele" datatype="rdf:PlainLiteral"></span><span id='am-236' property="rdfs:label" content="Gene mutation" datatype="rdf:PlainLiteral"></span><span id='am-237' property="rdfs:label" content="null allele" datatype="rdf:PlainLiteral"></span>mutation</span> using Sequencher software. <br />  <br />  <br />  <br />  <br />                                                 Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                                 Page 4 <br />  <br />  <br />                                Western Blot Analysis <br />                                             Cells harvested RIPA buffer (Santa Cruz Biotechnology Inc., sc-24948), subjected to <br />                                             SDS-PAGE, processed antibody manufacturer instruction (BD Biosciences). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             Antibodies used: anti-Yap 1:500 (H-125, Santa Cruz Biotechnology, Inc.), anti- <br />                                             phosphorylated-S127-Yap 1:500 (4911S, Cell Signaling Technologies), anti-cleaved- <br />                                             Caspase-3 1:1000 (9661S, Cell Signaling Technologies), anti-Caspase-8 1:1000 (3-1-9, BD <br />                                             Biosciences), anti-Lats-1 1:200 (A300-478A, Bethyl Laboratories Inc.), anti-Lats-2 1:200 <br />                                             (ST-3D10, CycLex Corp.), anti-actin 1:40,000 (AC40, Sigma Aldrich). <br />  <br />                                Immunofluorescence Imaging <br />                                             Cell lines Drosophila ovaries stained described (7) anti-myc 1:500 (9E10, <br />                                             BD Biosciences), Alexa-647 conjugated phalloidin 1:100 (Invitrogen), propidium iodide. <br />                                             Tissues visualized using Zeiss LSM confocal microscope, images minimally <br />                                             adjusted brightness contrast using Zeiss LSM510 Image Browser software. <br />  <br />                                Cell Proliferation Assays <br />                                             For cell count assay, 10,000 cells plated triplicate 12 plates counted on <br />                                             days 1 6 (prior confluence) using Beckman Coulter Z1 Particle Counter. To establish <br />                                             mitotic index, 10,000 cells plated cover slips, grown 4 days, stained with <br />                                             propidium iodide. Twenty images captured genotype mitotic index (number <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                             nuclei condensed chromosomes divided total number nuclei) scored. <br />  <br />                                Apoptosis Assay <br />                                             Cells incubated medium containing 30 &#206;&#188;M Cisplatin (Alexis Biochemicals, 400-040- <br />                                             M050) 48 hours. Floating adherent cells harvested western analysis. <br />  <br />                                Scratch Assay <br />                                             2.5 &#195;&#8212;106 cells plated T25 flasks medium containing 10 ug/ml Mitomycin C to <br />                                             block proliferation. Twelve hours later, cells scratched using 200 &#206;&#188;L pipette media <br />                                             replaced. Images 10 scratches cell line captured 30 minute recovery and <br />                                             location 10 hours later. Scratch areas measured using Ziess AxioVision <br />                                             Software 4.6. <br />  <br />                                Soft Agar Assay <br />                                             5,000 cells plated complete media plus 0.5% agar 6 plates triplicate. Media <br />                                             replaced 3 days. After 14 days, cells stained 2 ml 0.5 mg/ml MTT <br />                                             (dimethylthiazol diphenyltetrazolium bromide) 2 hrs. Visible colonies counted. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                Statistical Analysis <br />                                             For tissue microarray data, clinical immunohistochemistry variables summarized <br />                                             descriptively (Table 1). For 65 subjects complete IHC outcome data, disease <br />                                             specific survival, truncated 5 years, estimated Kaplan-Meier method, and <br />                                             compared groups (see below) using log-rank test. Patients survived, dropped <br />                                             study, died reasons unrelated cancer censored lesser last <br />                                             follow-up time 5 years. The contribution dichotomized nYap (L=0,1 vs H=2,3), <br />                                             dichotomized cpYap (L=0,1 vs H=2,3), combined dichotomized nY/cpY Category (3vs <br />                                             0,1,2), independent clinico-pathologic variables, analyzed stepwise Cox <br />                                             proportional hazards regression modeling. The following clinicopathologic variables were <br />                                             considered (categorized indicated): Stage (1,2,3,4 treated single &#226;&#8364;&#732;continuous&#226;&#8364;&#8482; variable <br />                                             univariate analysis indicated reasonable representation), dichotomized <br />  <br />  <br />                                                  Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                                 Page 5 <br />  <br />  <br />                                            Grade (H=3 vs including ungraded (n=2)), dichotomized histology (serous vs other). Cell <br />                                            culture experiments triplicate repeated times. Western <br />                                            immunofluorescence experiments repeated times. Student&#226;&#8364;&#8482;s Paired t test <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            used compare measured value control. P values &lt;.05 considered significant. <br />  <br />                                Results <br />                                Human Yap-S127A induces tumorigenesis Drosophila ovary <br />                                            Loss function clones warts fly ovarian follicular epithelium results tumor <br />                                            formation (7). We tested key Warts target, Yki, induces tumors. Using flp- <br />                                            technique, overexpressed wildtype Yki phosphorylation resistantYki-S168Ain the <br />                                            Drosophila ovarian follicular epithelium (not shown Fig. 1A), Yki-S168A, <br />                                            wildtype Yki, induced tumorigenesis. To test human homolog Yki, Yap, might <br />                                            play conserved role ovarian tumorigenesis, overexpressed wildtype Yap a <br />                                            phosphorylation resistant allele Yap, Yap-S127A, Drosophila ovarian follicular <br />                                            epithelium (not shown Fig. 1). Similar Yki, expression wildtype Yap effect, <br />                                            expression Yap-S127A resulted overproliferation loss epithelial architecture <br />                                            beginning mid-oogenesis. We conclude oncogenic capacity Yki fly ovary <br />                                            conserved human Yap. <br />  <br />                                Yap does appear activating mutations ovarian cancer <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            Since activating mutations Yap able induce tumors fly ovary, reasoned that <br />                                            Yap activated mutation ovarian cancer. Mutation of Lats <br />                                            consensus binding/phosphorylation sites Yap (16) result constitutive activation of <br />                                            Yap. We sequenced sites cDNAs synthesized cell RNA 10 ovarian <br />                                            cancer cell lines, 2 IOSE cell lines, 17 ovarian tumors, did detect non- <br />                                            synonymous mutations. We conclude Yap frequently mutated Lats <br />                                            consensus binding/phosphorylation sites ovarian cancer. We rule Yap might <br />                                            activated mutation low frequency and/or sites ovarian cancer. <br />  <br />                                Yap overexpressed phosphorylated S127 ovarian cancer cell lines <br />                                            Others shown Yap overexpressed hepatocellular carcinoma (12). To test Yap <br />                                            overexpressed ovarian cancer, performed western analysis 10 ovarian cancer cell <br />                                            lines IOSE cell lines (Supplementary Fig. 1A). Using antibody raised a <br />                                            fragment Yap1 contained Yap2 Yap2L, prominent 65 kDa band <br />                                            corresponding Yap2 (see below) evident western analysis. Yap2 expressed in <br />                                            cell lines Yap2 levels varied similar extent ovarian cancer cells control cell <br />                                            lines. Since Yap inhibited phosphorylation S127 Lats-1 orLats-2 kinases <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            (16), asked Lats kinases expressed Yap phosphorylated ovarian cancer <br />                                            cell lines (Supplementary Fig. 1A). Lats-1 Lats-2 expressed cell lines pYap <br />                                            levels varied similar extent ovarian cancer control cell lines (Supplementary Fig. <br />                                            1A). We conclude Yap overexpressed Yap phosphorylation S127 not <br />                                            grossly misregulated ovarian cancer cell lines. <br />  <br />                                Subcellular levels Yap pYap correlates ovarian cancer survival <br />                                            To explore possibility Yap misregulated ovarian cancer, reasoned that <br />                                            cytoplasmic retention primary mechanism controlling Yap nuclear accumulation <br />                                            (8), Yap subcellular distibution correlate patient survival ovarian cancer. After <br />                                            verifying specificity Yap pYap antibodies (Supplementary Fig. 1B), we <br />                                            established normal expression <span id='am-238' about='xsp:pattern' typeof='owl:Thing'>pattern</span> Yap pYap staining normal OSE. Similar <br />                                            previous report, Yap staining low undetectable (5/7) samples (17). When <br />  <br />  <br />                                                Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                               Page 6 <br />  <br />  <br />                                            Yap expressed OSE, localized predominantly nucleus (Fig. 2A) pYap <br />                                            localized predominantly cytoplasm (Fig. 2A). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            To determine Yap distribution correlates patient survival ovarian cancer, Yap and <br />                                            pYap localization levels evaluated 70 tumors ovarian cancer tissue <br />                                            microarray, contained mixture serous, clear cell, endometrioid, mucinous, and <br />                                            transitional carcinomas (Table 1). Kaplan-Meier estimation comparison disease specific <br />                                            survival high nuclear Yap (nYap) staining intensity (p=0.002) associated low <br />                                            cytoplasmic pYap (cpYap) staining intensity (p=0.07) marginally associated poor <br />                                            patient outcome (Fig. 2B). In contrast, cytoplasmic Yap staining intensity nuclear pYap <br />                                            staining intensity associated. Although nYap staining intensity remained significant <br />                                            independent marker poor patient survival (p=.0048, HR=3.3, 95% CI=1.03&#226;&#8364;&#8220;10.9) after <br />                                            considering clinical factors (data shown), sought determine combination <br />                                            nYap cpYap staining intensities showed stronger association poor patient <br />                                            survival. We sorted tumor categories based combination nYap <br />                                            cpYap staining intensities (Table 1). Cases high nYap low cpYap (nY/cpY <br />                                            Category 3) did significantly worse categories, combined they <br />                                            indistinguishable univariate survival analysis (Fig. 2B). Upon <br />                                            multivariate Cox regression analysis considered stage, high grade, serous histology, <br />                                            dichotomized nYap score, dichotomized cpYap score, dichotomized nY/cpY Category <br />                                            (3 vs other), stage (p&lt;0.001, HR=7.0, 95% CI: 3.0&#226;&#8364;&#8220;16.5) nY/cpY Category (p=0.002, <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            HR=7.8, 95% CI: 2.1&#226;&#8364;&#8220;28.9) significant. We conclude combination high nYap <br />                                            low cpYap strong independent predictor disease-specific survival ovarian cancer. <br />  <br />                                Yap overexpression promotes proliferation resistance apoptosis <br />                                            Correlations Yap staining poor patient survival does distinguish Yap <br />                                            merely correlates ovarian cancer outcome Yap active driver disease. To <br />                                            determine Yap active driver ovarian cancer progression, used IOSE cell line, <br />                                            80T vitro model. cDNA sequencing (above) indicated Yap2 predominantly <br />                                            expressed Yap isoform NOSE, IOSE, ovarian cancer cell lines. Yap1 Yap2L <br />                                            transcripts detected relatively low levels. <br />  <br />                                            Therefore, obtain IOSE cells high nuclear Yap, observed ovarian tumors, we <br />                                            overexpressedYap2, expected increase nuclear Yap mass action, and <br />                                            Yap2-5SA, resistant cytoplasmic retention phosphorylated by <br />                                            Lats (Fig. 3A) (16). Additionally knocked Yap shRNAs (Fig. 3A). Consistent <br />                                            Yap2 predominantly expressed isoform 80T cells, expressed Yap2, <br />                                            myc-tagged, ran slightly higher endogenously expressed isoform (Fig. <br />                                            3A). We determined localization Yap inYap2 Yap2-5SAoverexpressing cell <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                            lines (Fig. 3A). Although majority overexpressed Yap localizes cytoplasm, is <br />                                            nuclear Yap cells overexpressing Yap2 Yap2-5SA compared control cells (Fig. <br />                                            3A Supplementary Fig. 1B). <br />  <br />                                            To determine Yap regulates cell proliferation compared cell number Yap knockdown, <br />                                            overexpression, control cells days culture. 80T cells overexpressing Yap2 or <br />                                            Yap2-5SA contained significantly cells control, cells knocked Yap <br />                                            showed significant difference (Fig. 3B). The increase cell number to <br />                                            increased proliferation, decreased cell death, both. To determine Yap2 Yap2-5SA <br />                                            overexpressing cells increased proliferation, established mitotic index (Fig. 3B). <br />                                            Yap2 Yap2-5SA overexpression resulted significantly higher mitotic index compared to <br />                                            control, suggesting cultures proliferative. We asked effect might <br />                                            mediated EGF family ligand Amphiregulin, protein implicated ovarian cancer, <br />                                            acts downstream Yap breast cells promote proliferation (2,18). Amphiregulin <br />  <br />                                                Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                              Page 7 <br />  <br />  <br />                                           levels unchanged 80T cells overexpressing Yap2 Yap2-5SA western and <br />                                           IHC analysis (not shown). <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           To determine Yap expression decreases cell death, challenged cisplatin, the <br />                                           commonly used ovarian cancer chemotherapeutic agents (3). After 48 hours treatment, <br />                                           Yap2 Yap2-5SA overexpressing cells remained adherent culture dish, control <br />                                           shYap cells rounded detached (Fig. 3C), suggesting Yap2 overexpression <br />                                           protects apoptosis. To test Yap2 Yap2-5SA cells decreased apoptosis, we <br />                                           performed western analysis initiator effector caspases, Caspase-8 -3, respectively <br />                                           (19). Yap knockdown resulted higher levels cleaved Caspases, overexpression <br />                                           Yap2 Yap2-5SA showed decreased levels cleaved Caspase-8, increased levels full <br />                                           <span id='am-2' about='xsp:length' typeof='owl:Thing'>length</span> Caspase-8, small, reproducible, decrease cleaved caspase-3 (Fig. 3C). We <br />                                           conclude overexpression Yap2 Yap2-5SA results increased proliferation and <br />                                           decreased cisplatin-induced apoptosis, Yap knockdown results increased cisplatin- <br />                                           induced apoptosis. <br />  <br />                                Yap overexpression reduces contact inhibition promotes movement anchorage <br />                                independent growth <br />                                           In addition increased growth, aggressive tumor cells undergo epithelial mesenchymal <br />                                           transition (EMT), lose contact inhibition, develop increased motility, develop anchorage <br />                                           independent growth. We investigated processes Yap overexpressing knockdown <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                           cells. We noticed Yap2 Yap2-5SA overexpressing cells reached confluence, <br />                                           cell density higher (Fig. 4A), indicating loss contact inhibition. We that <br />                                           overexpression Yap2-5SA, overexpression Yap2 Yap knockdown, resulted in <br />                                           significantly faster wound closure (Fig. 4B). Further, cells overexpressing Yap2 Yap2-5SA <br />                                           formed colonies soft agar (Fig. 4C), control cells cells diminished Yap were <br />                                           unable grow. We conclude Yap promotes loss contact inhibition, cell migration, and <br />                                           growth soft agar. <br />  <br />                                           EMT associated loss contact inhibition, increased cell migration, increased <br />                                           growth soft agar Yap shown induce EMT human mammary epithelial <br />                                           cells (20). However, 80T cells appear mesenchymal (Fig 3A, C Fig 4B), express <br />                                           mesenchymal markers (Fibronectin Vimentin), express epithelial markers (E- <br />                                           cadherin, Occludin, &#206;&#178;-Catenin)(not shown). Yap knockdown Yap2 or <br />                                           Yap2-5SAoverexpression did alter expression markers (not shown). We <br />                                           conclude Yap promote loss contact inhibition, cell migration, growth soft <br />                                           agar independent EMT. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                Discussion <br />                                           We that, similar Yki, phosphorylation resistant human Yap able induce ovarian <br />                                           tumors expressed Drosophila ovary, suggesting ability Yap Yki to <br />                                           induce ovarian tumorigenesis conserved. Although evidence activating <br />                                           mutations Yap ovarian cancers, Yap overexpression cell lines, that <br />                                           sub-cellular levels Yap pYap correlate tend associate, respectively, survival <br />                                           ovarian cancer patients. Consistent role Yap ovarian cancer progression, we <br />                                           overexpression Yap2 phosphorylation-defective Yap2-5SA 80T cells <br />                                           resulted phenotypes associated cancer including increased proliferation, <br />                                           resistance cisplatin-induced apoptosis, faster cell migration, anchorage independent <br />                                           growth, knockdown Yap cells resulted increased sensitivity cisplatin- <br />                                           induced apoptosis. <br />  <br />  <br />  <br />  <br />                                               Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                                  Page 8 <br />  <br />  <br />                                          Paradoxically, Yap shown act tumor suppressor oncogene in <br />                                          breast cancer (20,21). However, studies attempted correlate Yap expression <br />                                          patient outcome, help resolve controversy. Three lines evidence refute <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          role Yap tumor suppressor ovarian cancer. First, low nYap expression ovarian <br />                                          tumors correlated better disease-specific survival. Second, Yap lost or <br />                                          dramatically down-regulated 10 ovarian cancer cell lines. Third, Yap knockdown 80T <br />                                          cells did result phenotypes associated cancer. In fact, Yap knockdown cells were <br />                                          sensitive cisplatin-induced apoptosis control cells (Fig. 3C). <br />  <br />                                          Although sample size modest interpreted cautiously, Yap appears a <br />                                          powerful prognostic marker poor survival ovarian cancer. Cox regression analysis the <br />                                          nY/cpY Category (3 vs 0, 1, 2,) revealed exceptionally high hazard ratio 7.7(comparable <br />                                          hazard ratio 7.0 stage), indicating that, data set, patients high nYap <br />                                          low cpYap nearly times greater risk death disease patients. <br />                                          This hazard ratio substantially higher hazard ratio nYap staining (HR=3.3). <br />                                          There explanations finding. First, immunohistochemical studies of <br />                                          archival tumor samples confounded systematic random errors inter- <br />                                          intra-sample heterogeneity differences age, fixation, processing, staining, and <br />                                          scoring tumor samples. Therefore, independent measures marker be <br />                                          expected reduce error. Second, nY/cpY Category reflect activity Yap the <br />                                          tumor. Yap phosphorylated S127 Lats kinases retained cytoplasm 14-3-3 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          (8). When Yap localized nucleus, likely transcriptionally active intense <br />                                          nYap staining suggests high Yap activity. In contrast, Yap phosphorylated the <br />                                          cytoplasm, Yap presumably transcriptionally inactive intense cpYap staining <br />                                          suggests low Yap activity. Thus, tumors nY/cpY Category 3, high levels nYap <br />                                          low levels cpYap, expected highest Yap activity. Analysis the <br />                                          levels Yap target genes nY/cpY Category shed light possibilities. <br />  <br />                                          An important question remains mechanism Yap misregulation ovarian cancer. <br />                                          We evidence Yap protein amplification Yap activating mutations. Further, <br />                                          pYap staining detectable 63/70 ovarian tumors ovarian cancer cell lines <br />                                          (Supplementary Fig. 1A), indicating increased nYap does likely result complete <br />                                          loss phosphorylation. A variety mechanisms described Drosophila alter <br />                                          Yki levels subcellular localization (8), providing possible mechanisms which <br />                                          nYap levels increase human ovarian cancer. Elucidation mechanisms likely <br />                                          provide insight therapeutic intervention targeting Yap. <br />  <br />                                          Our results support notion Yap excellent therapeutic target treatment <br />                                          ovarian cancer. Though sample size modest analysis needs confirmed <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          larger patient population, Yap distribution appears strong predictor survival <br />                                          ovarian cancer. Even analysis reveals hazard ratio nY/cpY Category <br />                                          3 low end 95% confidence interval, (2.1&#226;&#8364;&#8220;28.9), par EGF <br />                                          Her-2/neu, currently targeted clinical trials ovarian cancer treatments <br />                                          (22,23). Further, Yap activation results cancer-associated phenotypes while <br />                                          reduction Yap resulted increased sensitivity chemotherapy, indicating that <br />                                          therapies targeting Yap affect multiple cancer processes minimal deleterious effects. <br />  <br />                                          The Drosophila ovarian follicular epithelium human OSE female specific tissues that <br />                                          share important properties including mesodermal origin, monolayer cuboidal epithelial <br />                                          organization, hormone dependency, ability undergo dynamic remodeling (7,24&#226;&#8364;&#8220; <br />                                          26). The results presented support notion Drosophila follicular epithelium is <br />                                          useful tool discovery genes crucial pathogenesis ovarian cancer. <br />  <br />  <br />  <br />                                              Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                                            Page 9 <br />  <br />  <br />                                Supplementary Material <br />                                          Refer Web version PubMed Central supplementary material. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                Acknowledgments <br />                                          We thank George Halder, Kun-Liang Guan, Marius Sudol, Craig Allred, Michael Ittmann, Wendong Yu, Jianghua <br />                                          Wang, Yi Cai, Patricia Castro reagents advice, anonymous reviewers helpful suggestions. This <br />                                          work supported NIH 2RO1 CA087759-06A2 Mary Kay Ash 038-03 grants SG NIH RO1 CA103924 <br />                                          grant SO. CAH supported NIH training grant T32GM008307. <br />  <br />  <br />                                References <br />                                          1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin <br />                                             2009;59:225&#226;&#8364;&#8220;49. [PubMed: 19474385] <br />                                          2. Bast RC Jr, Hennessy B, Mills GB. The biology ovarian cancer: new opportunities translation. <br />                                             Nat Rev Cancer 2009;9:415&#226;&#8364;&#8220;28. [PubMed: 19461667] <br />                                          3. Cannistra SA. Cancer ovary. N Engl J Med 2004;351:2519&#226;&#8364;&#8220;29. [PubMed: 15590954] <br />                                          4. Sale S, Orsulic S. Models ovarian cancer metastasis: Murine models. Drug Discov Today Dis Models <br />                                             2006;3:149&#226;&#8364;&#8220;54. [PubMed: 19337569] <br />                                          5. Goode S, Perrimon N. Inhibition patterned cell shape change cell invasion Discs large during <br />                                             Drosophila oogenesis. Genes Dev 1997;11:2532&#226;&#8364;&#8220;44. [PubMed: 9334318] <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          6. Brumby AM, Richardson HE. Using Drosophila melanogaster map human cancer pathways. Nat <br />                                             Rev Cancer 2005;5:626&#226;&#8364;&#8220;39. [PubMed: 16034367] <br />                                          7. Zhao M, Szafranski P, Hall CA, Goode S. Basolateral junctions utilize warts signaling control <br />                                             epithelial-mesenchymal transition proliferation crucial migration invasion Drosophila <br />                                             ovarian epithelial cells. Genetics 2008;178:1947&#226;&#8364;&#8220;71. [PubMed: 18430928] <br />                                          8. Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway organ size control tumorigenesis: an <br />                                             updated version. Genes Dev 2010;24:862&#226;&#8364;&#8220;74. [PubMed: 20439427] <br />                                          9. Sudol M. Yes-associated protein (YAP65) proline-rich phosphoprotein binds SH3 <br />                                             domain Yes proto-oncogene product. Oncogene 1994;9:2145&#226;&#8364;&#8220;52. [PubMed: 8035999] <br />                                          10. Dong J, Feldmann G, Huang J, et al. Elucidation universal size-control mechanism Drosophila <br />                                               mammals. Cell 2007;130:1120&#226;&#8364;&#8220;33. [PubMed: 17889654] <br />                                          11. Zender L, Spector MS, Xue W, et al. Identification validation oncogenes liver cancer using <br />                                               integrative oncogenomic approach. Cell 2006;125:1253&#226;&#8364;&#8220;67. [PubMed: 16814713] <br />                                          12. Xu MZ, Yao TJ, Lee NP, et al. Yes-associated protein independent prognostic marker in <br />                                               hepatocellular carcinoma. Cancer 2009;115:4576&#226;&#8364;&#8220;85. [PubMed: 19551889] <br />                                          13. Miao J, Mu D, Ergel B, et al. Hepsin colocalizes desmosomes induces progression ovarian <br />                                               cancer mouse model. Int J Cancer 2008;123:2041&#226;&#8364;&#8220;7. [PubMed: 18726901] <br />                                          14. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic predictive factors breast cancer by <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                               immunohistochemical analysis. Mod Pathol 1998;11:155&#226;&#8364;&#8220;68. [PubMed: 9504686] <br />                                          15. Auersperg N, Siemens CH, Myrdal SE. Human ovarian surface epithelium primary culture. In <br />                                               Vitro 1984;20:743&#226;&#8364;&#8220;55. [PubMed: 6083974] <br />                                          16. Zhao B, Wei X, Li W, et al. Inactivation YAP oncoprotein Hippo pathway involved in <br />                                               cell contact inhibition tissue growth control. Genes Dev 2007;21:2747&#226;&#8364;&#8220;61. [PubMed: 17974916] <br />                                          17. Steinhardt AA, Gayyed MF, Klein AP, et al. Expression Yes-associated protein common solid <br />                                               tumors. Hum Pathol 2008;39:1582&#226;&#8364;&#8220;9. [PubMed: 18703216] <br />                                          18. Zhang J, Ji JY, Yu M, et al. YAP-dependent induction amphiregulin identifies non-cell- <br />                                               autonomous component Hippo pathway. Nat Cell Biol 2009;11:1444&#226;&#8364;&#8220;50. [PubMed: 19935651] <br />                                          19. Riedl SJ, Salvesen GS. The apoptosome: signalling platform cell death. Nat Rev Mol Cell Biol <br />                                               2007;8:405&#226;&#8364;&#8220;13. [PubMed: 17377525] <br />                                          20. Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties YAP, candidate oncogene <br />                                               chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006;103:12405&#226;&#8364;&#8220;10. [PubMed: <br />                                               16894141] <br />  <br />  <br />                                               Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                                   Page 10 <br />  <br />  <br />                                          21. Yuan M, Tomlinson V, Lara R, et al. Yes-associated protein (YAP) functions tumor suppressor <br />                                              breast. Cell Death Differ 2008;15:1752&#226;&#8364;&#8220;9. [PubMed: 18617895] <br />                                          22. Mackay HJ, Oza AM. Other new targets. Int J Gynecol Cancer 2009;19 (Suppl 2):S49&#226;&#8364;&#8220;54. [PubMed: <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              19955915] <br />                                          23. Graeff P, Crijns AP, Jong S, et al. Modest effect p53, EGFR HER-2/neu prognosis <br />                                              epithelial ovarian cancer: meta-analysis. Br J Cancer 2009;101:149&#226;&#8364;&#8220;59. [PubMed: 19513073] <br />                                          24. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, <br />                                              endocrinology, pathology. Endocr Rev 2001;22:255&#226;&#8364;&#8220;88. [PubMed: 11294827] <br />                                          25. Wu X, Tanwar PS, Raftery LA. Drosophila follicle cells: morphogenesis eggshell. Semin Cell <br />                                              Dev Biol 2008;19:271&#226;&#8364;&#8220;82. [PubMed: 18304845] <br />                                          26. Szafranski P, Goode S. A Fasciclin 2 morphogenetic switch organizes epithelial cell cluster polarity <br />                                              motility. Development 2004;131:2023&#226;&#8364;&#8220;36. [PubMed: 15056617] <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                         Page 11 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          Figure 1. <br />                                          Drosophila Yki-S168A human Yap-S127A overexpression induces tumorigenesis the <br />                                          Drosophila ovary. A. Confocal section wildtype Drosophila egg chamber (upper) <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          stained propidium iodide reveal nuclei phalloidin reveal cell cortices. <br />                                          Follicle cells (small nuclei, arrow heads) form monolayer epithelium germ cells <br />                                          (large nuclei, arrows). In egg chambers follicle cells overexpress fly Yki-S168A <br />                                          (middle) human Yap-S127A (lower) follicular epithelium multilayered has <br />                                          supernumerary follicle cells. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                           Page 12 <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          Figure 2. <br />                                          Yap pYap associate disease-specific survival. A. OSE (left) serous ovarian tumor <br />                                          (right) stained Haematoxylin (blue) reveal cell nuclei, Yap (top; brown OSE, <br />                                          red tumor) pYap (bottom, brown). In OSE tumors, Yap localizes primarily the <br />                                          nucleus (arrows) pYap localizes primarily cytoplasm (arrowheads). B. Kaplan-Meier <br />                                          estimates disease-specific survival (truncated 5 years) patients high verses low <br />                                          nYap (left), high versus low cpYap (middle), nY/cpY Category 3 (high nYap low <br />                                          cpYap) vs nY/cpY Categories (0, 1, 2)(right)(see table 1). P-values Log-rank tests <br />                                          shown. <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                              Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                           Page 13 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          Figure 3. <br />                                          Yap overexpression promotes proliferation resistance apoptosis. A. Western analysis <br />                                          (left) Yap pYap 80T cells expressing nontargeting shRNA, shRNAs targeting Yap <br />                                          (shYap7,8,9), vector (overexpression control), Yap2-myc, Yap2-5SA-myc. The <br />                                          blot right exposed shorter time. Immunofluorescence staining (right) myc <br />                                          DNA 80T cells expressing Yap2-myc Yap2-5SA-myc. For clarity, fields were <br />                                          selected contain fewer overexpressing cells typically observed. A higher portion of <br />                                          overexpressed Yap2-5SA localizes nucleus (arrowheads) compared overexpression <br />                                          Yap2 (arrows). B. Quantification cell number (left) Yap knockdown and <br />                                          overexpressing cells days growth. Control Yap2-5SA cells stained DNA <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          (middle) reveal condensed DNA mitotic cells (asterics). Quantification mitotic index <br />                                          (right). C. Light micrographs cells treated 30 &#206;&#188;M cisplatin 48 hours (left) show <br />                                          morphology adherent cells (arrows) nonadherent cells (arrowheads). Western analysis <br />                                          (right) length Caspase-8 (C8-FL), cleaved Caspase-8 (cC8), cleaved Caspase-3 <br />                                          (cC3) cells treated 30 &#206;&#188;M cisplatin 48 hours.*p&lt;.05, **p&lt;.01, ***p&lt;.001. <br />  <br />  <br />  <br />  <br />                                              Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                            Page 14 <br /> NIH-PA Author Manuscript <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          Figure 4. <br />                                          Yap overexpression reduces contact inhibition promotes wound closure anchorage <br />                                          independent growth. A. Micrographs confluent cultures stained DNA reveal cell <br />                                          density. Greater fluorescence intensity reveals multilayering cells. B. Representative bright <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                          field micrographs (left) control Yap2-5SA cells 0.5 10 hours wounding. <br />                                          Quantification wound closure (right) 10 hours. C. Representative micrograph cell <br />                                          colonies visualized MTT (left) 14 days growth soft agar. Quantification the <br />                                          number colonies (right).*p&lt;.05 ***p&lt;.001. <br />  <br />  <br />  <br />  <br />                                              Cancer Res. Author manuscript; available PMC 2011 November 1. <br />                             Hall et al.                                                                                                                         Page 15 <br />  <br />  <br />  <br />  <br />                                                                                             Table 1 <br />                            Distribution clinical characteristics ovarian cancer patients included study. <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                                       N       % <br />  <br />                             Total                     70    100.0 <br />  <br />                             FIGO Stage <br />  <br />                                Stage I                23     32.9 <br />                                Stage II               11     15.7 <br />                                Stage III              29     41.4 <br />                                Stage IV               7      10.0 <br />                             Tumor Type <br />  <br />                                Serous                 26     37.1 <br />                                Clear Cell             17     24.3 <br />                                Endometriod            17     24.3 <br />                                Mucinous               6       8.6 <br />                                Transitional           4       5.7 <br />                             Tumor Grade <br /> NIH-PA Author Manuscript <br />  <br />  <br />  <br />  <br />                                Grade 1                7      10.0 <br />                                Grade 2                22     31.4 <br />                                Grade 3                39     55.7 <br />                                Missing                2       2.9 <br />                             nYap <br />  <br />                                Low                    42     60.0 <br />                                High                   25     35.7 <br />                                Missing                3       4.3 <br />                             cpYap <br />  <br />                                Low                    39     55.7 <br />                                High                   28     40.0 <br />                                Missing                3       4.3 <br />                             nY/cpY Category <br />  <br />                                      nYap     cpYap <br />  <br />                                0     low      h <br /> </body></html>